Oligonucleotide Biopolymers - Future Challenges for Chromatography

HPLC, UHPLC

Oligonucleotide Biopolymers - Future Challenges for Chromatography

24 Mar, 2011

Published over 15 years ago. See the latest and most current information on HPLC, UHPLC.

George Okaf, Daren S Levin and David Elder
1 min read
Download

Synthetic Oligonucleotides as Therapeutic Medicines

Synthetic oligonucleotides are an exciting new class of biomolecules capable of treating many disorders, which are currently not amenable to existing drugs, including viral infections [1], respiratory disorders [2], cancers [3] and rare diseases [4]. Current interest has been largely fuelled by two key events: firstly, Fire and Mello’s Nobel-prize winning discovery of gene silencing by RNA interference (which helped to improve our understanding of the genetic basis of many diseases) [5]; and secondly, the regulatory approval of two oligonucleotide-based drugs, namely Vitravene® [6] (a 21-base single stranded antisense oligonucleotide approved by the FDA in 1998 for cytomegalovirus infections) and Macugen® [7] (a pegylated aptamer approved in 2005 for treating wet macular degeneration).

Latest Articles

Explore Our Other Sites

Labmate Online
Physics-based machine learning sharpens images taken through through fog, tissue, cloudy liquids
Explore more Arrow
Envirotech Online
East Asia expands cooperative POPs monitoring with greater focus on PFAS analysis
Explore more Arrow
Pollution Solutions Online
Leading UK biogas operator places first orders for new FlowSep technology
Explore more Arrow
Petro Online
Beyond standard cetane testing: Unlocking research for the next generation of sustainable fuels
Explore more Arrow